生物活性

• 描述HSP90 (heat shock protein 90) is a cellular ubiquitous molecular chaperone responsible for promoting the conformational mutation and stabilization of several client oncoproteins, including Met, B-Raf, p53, Akt, and Kit, function of which is required by tumor cells to maintain appropriate client protein expression necessary for proliferation and survival. 17-AAG is a geldanamycin-derived HSP90 inhibitor with 100-fold higher binding affinity for Hsp90 derived from tumour cells (IC50=6nM, measured by competitive binding assays using a biotinylated GM probe) than normal cells, which may due to the high ATPase activity of tumour Hsp90 by co-chaperones^[1]. Exposure to 5μM 17-AAG reduced Bcr-Abl protein levels in HL-60/Bcr-Abl and K562 cells, and also down-regulated the levels of c-Raf in Bcr-Abl-positive cells and the control HL-60/neo cells. Induced cell apoptosis of HL-60/neo, HL-60/Bcr-Abl and K562 cells can be observed after exposure to 5μM 17-AAG for 24-72h^[2]. Intraperitoneal injection with 17-AAG at different doses ranging in 5-40mg/kg every other day for three weeks prolonged the survival of mice injected with TGB lymphoma cells. Administration of 40mg/kg 17-AAG effectively impaired the self-renewal of the lymphoma CSCs in vivo^[3].
• 作用机制1. 17-AAG is a geldanamycin-derived HSP90 inhibitor which can bind to the N-terminal ATP/ADP-binding domain of Hsp90. 2. As tumour cells gradually accumulate mutant and over expressed signalling proteins, this makes HSP90 become engaged in active chaperoning and stabilization of oncoproteins. This will make HSP90 adopt a high affinity form induced by bound co-chaperone proteins and make HSP90 possess higher activity in tumour cells. This can explain why 17-AAG showed higher binding affinity for Hsp90 derived from tumour cells^[1].
• 细胞研究
• Cell Data

  Cell Lines	Concentration	Assay Type	Time	Activity Description	Data Sources
  22RV1	-	Growth Inhibition Assay	-	IC50=3.49168 μM	SANGER
  23132-87	-	Growth Inhibition Assay	-	IC50=0.0695 μM	SANGER
  5637	-	Growth Inhibition Assay	-	IC50=0.0574 μM	SANGER

• 更多

• 动物研究
  剂量	Mice: 20 mg/kg - 60 mg/kg[4] (i.v.), 40 mg/kg[4] (p.o.), 25 mg/kg[5] (i.p.), 100 mg/kg[6] (i.p.)
  给药途径	i.v., p.o., i.p.
  动物药代数据	Animal Mice[4] Dose 60 mg/kg Administration i.v. Vc 4536 ml/kg CLtotal 44 ml/min/kg Kcp 0.009 Kpc 0.005 T1/2β 309 min Ke 0.01 Vdss 12800 ml/kg T1/2α 32 min

• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT00546780	Multiple Myeloma	Phase 3	Completed	-	-
  NCT00303797	Refractory Chronic Lymphocytic... more >> Leukemia Refractory Multiple Myeloma Stage III Multiple Myeloma Stage IV Chronic Lymphocytic Leukemia Unspecified Adult Solid Tumor, Protocol Specific Collapse <<	Phase 1	Completed	-	United States, Minnesota ... more >> Mayo Clinic Rochester, Minnesota, United States, 55905 Collapse <<
  NCT00082966	Adult Lymphocyte Depletion Hod... more >>gkin Lymphoma Adult Mixed Cellularity Hodgkin Lymphoma Adult Nodular Sclerosis Hodgkin Lymphoma Recurrent Adult Hodgkin Lymphoma Collapse <<	Phase 2	Completed	-	United States, Illinois ... more >> Cancer and Leukemia Group B Chicago, Illinois, United States, 60606 Collapse <<

• 更多